511
Participants
Start Date
September 2, 2011
Primary Completion Date
July 4, 2016
Study Completion Date
July 4, 2016
Delamanid + OBR
The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
Placebo + OBR
Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
Quezon City
Quezon City
Makati City
Klerksdorp
Durban
Dasmariñas
Cape Town
Tartu
Riga
Šiauliai
Vilnius
Chisinau
Vorniceni
Alfonso Ugarte
Lima Cercado
Comas
El Agustino
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY